Ten-Year Results of the Press Fit Condylar Sigma Cobalt –Chrome Total Knee Replacement
J Knee Surg DOI: 10.1055/s-0038-1641138Total knee arthroplasty (TKA) is reliant on safe and effective implants. The Press Fit Condylar Sigma Cobalt–Chrome (PFCSCC) was introduced in 2006, but no reports have examined long-term failure rates and patient-reported outcome measures (PROMs). The primary aim of this study was to assess survival outcomes of the PFCSCC at 10 years after implantation. Prospective data collection was performed on all patients undergoing primary TKA in one orthopaedic department using this prosthesis exclusively from February 1, 2006, to January 31, 2007. Follow-up was at 10 years. Survival analysis was performed using two primary outcome measures: (1) all-cause joint revision and (2) aseptic revision. Secondary outcomes measures included the American Knee Society Score (AKSS) and Oxford Knee Score (OKS). In total, 249 knees of 233 patients underwent primary TKA. Mean patient age was 66.7 years (range 34–80), and mean body mass index (BMI) was 30 kg/m2 (20.7–40.1). Reviewing all causes of revisions, 14 joints (5.6%) of 14 patients required reoperation. Of these, nine were for deep infection, including six in the first year. Four (1.6%) underwent aseptic revision. Mean AKSS changed from 47.6 to 90.4 (n = 140; p
Abstract Laryngeal trauma from prolonged endotracheal intubation occurs in patients of all ages. Most changes are superficial and heal quickly. Injuries that are found consistently during intubation include nonspecific changes, edema, granulation tissue, ulceration, and othermiscellaneous injuries. In thispapersignificant, severe, and lasting trauma of the larynx has been classified on thebasis of theknown factors in pathogenesis, observations made atendoscopy, and photographic documentation. This classification has required introduction of new descriptive terminology: "tongues of granulation tissue," &q...
PMID: 30012011 [PubMed - in process]
PMID: 30012010 [PubMed - in process]
PMID: 30012009 [PubMed - in process]
The FDA has approved the first protease inhibitor-based single-tablet regimen for the treatment of HIV-1 infection in treatment-naive and certain virologically suppressed adult patients.FDA Approvals
Publication date: August 2018Source: The Lancet Neurology, Volume 17, Issue 8Author(s): Henk-Jan Westeneng, Ammar Al-Chalabi, Orla Hardiman, Thomas PA Debray, Leonard H van den Berg
Publication date: August 2018Source: The Lancet Neurology, Volume 17, Issue 8Author(s): Susana Carmona, Kathleen Zahs, Elizabeth Wu, Kelly Dakin, Jose Bras, Rita GuerreiroSummaryAlzheimer's disease is a genetically complex disorder; rare variants in the triggering receptor expressed on myeloid cells 2 (TREM2) gene have been shown to as much as triple an individual's risk of developing Alzheimer's disease. TREM2 is a transmembrane receptor expressed in cells of the myeloid lineage, and its association with Alzheimer's disease supports the involvement of immune and inflammatory pathways in the cause of the disease, rather th...
Publication date: August 2018Source: The Lancet Neurology, Volume 17, Issue 8Author(s): Farhat Husain, Jerry Vanatta
Publication date: August 2018Source: The Lancet Neurology, Volume 17, Issue 8Author(s):
Publication date: August 2018Source: The Lancet Neurology, Volume 17, Issue 8Author(s): Lee H Schwamm